Highlights
- A meta-analysis of 19 double-blind RCTs involving over 120,000 participants found no evidence for 62 out of 66 adverse effects currently listed on statin labels.
- Beyond muscle symptoms and diabetes, only four outcomes—abnormal liver tests, urinary composition changes, and edema—showed a statistically significant increase.
- Commonly reported issues such as cognitive impairment, depression, and sleep disturbances were not supported by the blinded data.
- The findings suggest that current product labels may unnecessarily contribute to the nocebo effect and treatment non-adherence.
Background: The Disconnect Between Labels and Evidence
Specialty calculators
For clinical reference; use professional judgment.
